Status: Ongoing
First registered on:
22/02/2019
Last updated on:
26/02/2019
1. Study identification
EU PAS Register NumberEUPAS28375
Official titleUSE OF PSYCHOTROPIC DRUGS IN CHILDREN AND ADOLESCENTS IN CATALONIA. A cohort study with real world data from the electronic primary health care record from 2007-2017.
Study title acronymPEPSICAT
Study typeObservational study
Brief description of the studyThis project has four main objectives: to describe in children <18 years the use of psychotropic drugs during the last decade, to describe their psychiatric diagnoses, to describe the baseline characteristics when starting treatment with psychotropic drugs and, to describe the consumption pattern of psychotropic drugs. As secondary objectives: to analyse factors associated with the use of different psychotropic drugs and factors related to the diagnosis of mental illness in patients under treatment with psychotropic drugs and to describe the adherence to psychotropic treatment. As exploratory objectives, an attempt will be made to correlate the maternal obstetric and psychiatric history with the consumption of psychotropic medication in the offspring and to analyse the reasons for the lack of a diagnostic record of mental pathology in patients with psychotropic treatment.
Methods: Descriptive observational study will from 2007-2017 in the population under the age of 18 with at least one prescription for a psychotropic drug. Two studies will be carried out: one to estimate the prevalence of psychotropic drug use and psychiatric pathology diagnoses and the second one to estimate the incidence of psychotropic drug use in the <18 year population. This population will be followed until the end of the study or the impossibility to obtain information (death/transfer). The treatment period with this first psychotropic drug and the addition of other psychotropic drugs or the change of psychotropic treatment will be analysed during the follow-up. Data source: SIDIAP (Sistema de Información para el Desarrollo de la Investigación en Atención Primaria) database, which contains anonymized clinical information on approximately 80% of the population of Catalonia (Spain). Information will be completed with data from the Basic Minimum Data Set for outpatient mental health care (CMBD-SMA). Data will be stratified by sex and age groups.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableCatalan Health Department SLT006/17/00309
https://web.gencat.cat/web/shared/OVT/Departaments/SLT/Documents/Formularis_pdf/SUBV_Recerca_Resolucio-definitiva-de-concessio-de-la-subencio-PERIS-2018-2020.pdf
AEMPS classification: EPA-OD. UMO 2007-17. Code: IUI-FLU-2018-01
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIDIAPJGol
Department/Research groupInstitut Universitari d'Investigació en Atenció Primària Jordi Gol
Organisation/affiliationIDIAPJGol
Details of (Primary) lead investigator
Title Dr
Last name Ainhoa
First name Gomez-Lumbreras
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Spain
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed16/02/2018
Start date of data collection01/06/201801/06/2018
Start date of data analysis14/06/2018
Date of interim report, if expected05/10/201805/10/2018
Date of final study report31/12/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government bodyCatalan Health Department100
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Gome-Lumbreras
First name Ainhoa
Address line 1Gran Via de les Corts Catalanes 587-àtic
Address line 2
Address line 3
CityBarcelona
Postcode08007
CountrySpain
Phone number (incl. country code)34-934824605
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Gomez-Lumbreras
First name Ainhoa
Address line 1Gran Via de les Corts Catalanes 587-àtic
Address line 2
Address line 3
CityBarcelona
Postcode08007
CountrySpain
Phone number (incl. country code)34-934824605
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N06BA (Centrally acting sympathomimetics)
Substance class (ATC Code)N06A (ANTIDEPRESSANTS)
Substance class (ATC Code)N05A (ANTIPSYCHOTICS)
Substance class (ATC Code)N05B (ANXIOLYTICS)
Substance class (ATC Code)N05C (HYPNOTICS AND SEDATIVES)
7. Medical conditions to be studied
Medical condition(s)Yes
Psychiatric investigation
8. Population under study
Age
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects300000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
To describe the use of psychotropic drugs in children <18 years from Catalonia during 2007-2017.
To describe the psychiatric diagnoses in the <18 years population consuming psychotropic drugs.
To describe the consumption pattern and characteristics of patients <18 years who start treatment with psychotropic drugs.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Since the first psychotropic prescription till the end of the study patients will be follow-up to describe their baseline characteristics, psychiatric diagnoses as well as changes, adherence regarding the psychotropic treatment.
15. Data analysis plan
Please provide a brief summary of the analysis method
All data management, purification, descriptive calculation and statistical analysis processes will be carried out using the statistical package R 3.3(2016)
Demographic data and baseline characteristics of the population will be described by relative and absolute frequencies for the categorical variables and median standard deviation or median and interquartile range for the continuous variables.
In the bivariate analysis, Chi-square test or the exact Fischer test for the categorical variables and the t-test of Student or the U-test of Mann-Whitney for the continuous variables according to their distribution
Evaluation of psychotropic consumption based on psychiatric/obstetric maternal records, as well as the risk related to the persistence/adherence of these in patients with an age range of 16 to 18 years old, will be performed using multiple logistic regression models or proportional risk models (Cox).Adjustment for risk factors based on the characteristics of the study population
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
